Episode 1, Part 3 of PharmTech AI Pulse Check covers why INTerpath-001's AI isn't ChatGPT and names pharma manufacturing's biggest AI governance gaps.
|Articles|March 2, 2018
- Pharmaceutical Technology-03-02-2018
- Volume 42
- Issue 3
Pharmaceutical Technology, March 2018 Issue (PDF)
Click the title above to open the Pharmaceutical Technology March 2018 issue in an interactive PDF format.
Advertisement
Articles in this issue
over 8 years ago
AR/VR Simulator for Plant Personnel Trainingover 8 years ago
Five-Hundred-Gallon Multi-Shaft Mixerover 8 years ago
Tackling Medicine Shortages in Europeover 8 years ago
A New Method for Risk Assessment of Pharmaceutical Excipientsover 8 years ago
FDA Heightens Drive for Transparencyover 8 years ago
Current Challenges in Bioprocesses Developmentover 8 years ago
Dissolved Oxygen Sensorover 8 years ago
Twin Screw Extruder Systemover 8 years ago
Computerized Systems ValidationAdvertisement
Related to this article
Michael Levy, senior vice president, Digital & Innovation, USP, explains the digital supply chain in a preview of his upcoming CPHI Milan panel presentation, The Next Phase of Pharma Supply Chains.
FDA approves tavapadon, first D1/D5 agonist, validating AbbVie's $8.7B Cerevel deal and an October five-strength oral tablet launch.
Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Merck licenses SciBrunch's preclinical KRAS G12D inhibitor for $2.13B, raising tech transfer and scale-up questions for oral cancer drug development.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Advertisement
Advertisement